Maria Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maria Zhang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ali Naji
Institute for Immunology & Immune Health (I3H), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
1 shared publication - Chengyang Liu
Institute for Diabetes, Obesity, and Metabolism
1 shared publication - Chih-Chi Andrew Hu
Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, USA
1 shared publication - Chih-Hang Anthony Tang
The Wistar Institute, Philadelphia, Pennsylvania
1 shared publication - Jiandie D. Lin
Life Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
1 shared publication - Ling Qi
Department of Molecular Physiology and Biological Physics, University of Virginia School of Medicine, Charlottesville, USA
1 shared publication
Latest Publications
- Open Access
- 1 July 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (7) , 3499-3510
Sel1L-Hrd1 ER-associated degradation maintains β cell identity via TGF-β signaling
β Cell apoptosis and dedifferentiation are 2 hotly debated mechanisms underlying β cell loss in type 2 diabetes; however, the molecular drivers underlying such events remain largely unclear. Here, we performed a side-by-side comparison of mice carrying β cell–specific deletion of ER-associated degradation (ERAD) and autophagy. We reported that, while autophagy was necessary for β cell survival, the highly conserved Sel1L-Hrd1 ERAD protein complex was required for the maintenance of β cell maturation and identity. Using single-cell RNA-Seq, we demonstrated that Sel1L deficiency was not associated with β cell loss, but rather loss of β cell identity. Sel1L-Hrd1 ERAD controlled β cell identity via TGF-β signaling, in part by mediating the degradation of TGF-β receptor 1. Inhibition of TGF-β signaling in Sel1L-deficient β cells augmented the expression of β cell maturation markers and increased the total insulin content. Our data revealed distinct pathogenic effects of 2 major proteolytic pathways in β cells, providing a framework for therapies targeting distinct mechanisms of protein quality control.
- 1 July 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (7) , 3499-3510
Open AccessSel1L-Hrd1 ER-associated degradation maintains β cell identity via TGF-β signaling
β Cell apoptosis and dedifferentiation are 2 hotly debated mechanisms underlying β cell loss in type 2 diabetes; however, the molecular drivers underlying such events remain largely unclear. Here, we performed a side-by-side comparison of mice carrying β cell–specific deletion of ER-associated degradation (ERAD) and autophagy. We reported that, while autophagy was necessary for β cell survival, the highly conserved Sel1L-Hrd1 ERAD protein complex was required for the maintenance of β cell maturation and identity. Using single-cell RNA-Seq, we demonstrated that Sel1L deficiency was not associated with β cell loss, but rather loss of β cell identity. Sel1L-Hrd1 ERAD controlled β cell identity via TGF-β signaling, in part by mediating the degradation of TGF-β receptor 1. Inhibition of TGF-β signaling in Sel1L-deficient β cells augmented the expression of β cell maturation markers and increased the total insulin content. Our data revealed distinct pathogenic effects of 2 major proteolytic pathways in β cells, providing a framework for therapies targeting distinct mechanisms of protein quality control.